Deciphera intends to use the net proceeds of the offering to continue funding the development of vimseltinib, including in its ongoing pivotal Phase 3 MOTION study of vimseltinib in patients with tenosynovial giant cell tumors currently underway, additional clinical trials as well as outsourcing of clinical research and manufacturing of trial materials and pre-commercial and medical business capabilities related to vimseltinib; to fund development of DCC-3116, including multiple Phase 1b combination studies and potential Phase 2 expansion combination cohorts in multiple tumor types, as well as clinical research outsourcing and hardware manufacturing clinical trial; to fund research and development of Deciphera’s pan-RAF program and other new research activities for potential drug candidates from its proprietary kinase switch control inhibitor platform; and the remainder for working capital purposes, including general operating expenses.

JP Morgan and Jefferies are acting as joint bookrunners for the offering.

The securities described above are offered by Deciphera pursuant to a shelf registration statement on Form S-3 (#333-236389) which was declared effective by the Securities and Exchange Commission (SEC) on March 10, 2022. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering was filed with the SEC on April 26, 2022 and is available on the SEC’s website at . A copy of the final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and may be obtained, when available, by contacting: JP Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by phone at 866-803-9204, or by email at [email protected]; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by phone at 877-821-7388 or by email at [email protected]

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, and there will be no sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on the discovery, development and commercialization of important new medicines to improve the lives of people with cancer. We leverage our proprietary platform of switch-driven kinase inhibitors and deep expertise in kinase biology to develop a broad pipeline of innovative drugs. In addition to advancing several product candidates from our platform into clinical studies, QINLOCK® is Deciphera’s switch control inhibitor for the treatment of fourth-line GISTs. QINLOCK is approved in Australia, Canada, China, European Union, Hong Kong, Switzerland, Taiwan, United Kingdom and United States. For more information, visit and follow us on LinkedIn and Twitter (@Deciphera).

Caution Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements relating to the timing and completion of the proposed offering and the intended use of the proceeds of the proposed offer. . The words “may”, “will”, “could”, “should”, “should”, “expect”, “plan”, “anticipate”, “intend”, “believe”, ” estimates’, ‘predicts’, ‘project’, ‘potential’, ‘pursue’, ‘target’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. All forward-looking statements contained in this press release are based on management’s current expectations and beliefs and are subject to a number of important risks, uncertainties and factors that may cause actual events or results to differ. differ materially from those expressed or implied by any forward-looking statement. statements contained in this press release. These risks and uncertainties include fluctuations in Deciphera’s stock price, changes in market conditions, the satisfaction of customary closing conditions relating to the public offering, and other risks identified in our filings with the SEC, including including our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, and subsequent filings with the SEC. We caution you not to place undue reliance on forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which such statements may be based, or which may affect the likelihood that actual results will differ from those set forth in forward-looking statements.

Deciphera, the Deciphera logo, QINLOCK and the QINLOCK logo are registered trademarks of Deciphera Pharmaceuticals, LLC.

See the source version on